Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beloranib - Chong Kun Dang/ Zafgen

Drug Profile

Beloranib - Chong Kun Dang/ Zafgen

Alternative Names: 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate; Beloranib hemioxalate; CKD-732; TNP-470 analogue; ZGN-433; ZGN-440

Latest Information Update: 02 Aug 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chong Kun Dang
  • Developer Chong Kun Dang; Zafgen
  • Class Antineoplastics; Cyclohexanes; Obesity therapies; Sesquiterpenes; Small molecules; Unsaturated fatty acids
  • Mechanism of Action Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroectodermal tumours; Prader-Willi syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Obesity; Prader-Willi syndrome; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 19 Jul 2016 Discontinued - Phase-I for Colorectal cancer (Combination therapy) in South Korea (IV)
  • 19 Jul 2016 Discontinued - Phase-I for Solid tumours in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top